Turn Therapeutics Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Turn Therapeutics Inc. (TTRX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $19.38 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- Turn Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$104.36K.
- Turn Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $123.74K, a 56.91% decline year-over-year.
- Turn Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$68.28K, a 131.23% decline year-over-year.
- Turn Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$15.44K.
- Turn Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$105.03K, a 151.36% decline from fiscal 2024.
- Turn Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $204.50K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$104.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $19.38K 10-Q · filed 2026-08-12 | -$48.90K derived: sum of 3 quarters · filed 2026-08-12 | -$64.33K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $123.74K 10-Q · filed 2026-05-11 | $55.45K derived: sum of 2 quarters · filed 2026-05-11 | $40.02K derived: sum of 3 quarters · filed 2026-05-11 | -$268.43K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$68.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$83.72K derived: sum of 2 quarters · filed 2026-03-31 | -$392.17K derived: sum of 3 quarters · filed 2026-08-12 | -$105.03K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$15.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$323.88K derived: sum of 2 quarters · filed 2026-08-12 | -$36.74K 10-Q · filed 2025-11-13 | $181.92K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$308.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$21.31K 10-Q · filed 2026-08-12 | $197.35K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $287.14K 10-Q · filed 2026-05-11 | $505.80K derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $218.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $204.50K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | -$14.15K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |